{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"67.05","value":"-28.7"},{"groupId":"OG001","spread":"70.89","value":"-33.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"71"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"OG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"OG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"OG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG003","title":"Part 2"}],"paramType":"MEAN","populationDescription":"PSA Response Evaluable Population. There were no participants in the Control Arm that were part of the PSA Response Evaluable Population. Participants in Part 2 did not have mCRPC, so were not assessed using PSA measurement.","reportingStatus":"POSTED","timeFrame":"Every 4 weeks throughout study participation. Average duration of participation, 10 months.","title":"Part 1: Best PSA Percent Change","type":"SECONDARY","unitOfMeasure":"percent change from baseline"}